{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:33:44Z","timestamp":1784046824730,"version":"3.55.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,17]]},"DOI":"10.7759\/cureus.67080","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T16:20:29Z","timestamp":1723911629000},"source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review"],"prefix":"10.7759","author":[{"given":"Sultan","family":"Alfawaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhadi","family":"Burzangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Esmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2021.42.5.20200676","article-title":"Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council Countries","volume":"42","author":"Aljulifi MZ","year":"2021","unstructured":"Aljulifi MZ. Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council Countries. Saudi Med J. 2021, 42:481-90. 10.15537\/smj.2021.42.5.20200676","journal-title":"Saudi Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova K","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al.. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017, 128:40-50. 10.1016\/j.diabres.2017.03.024","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications","volume":"13","author":"Wondmkun YT","year":"2020","unstructured":"Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020, 13:3611-6. 10.2147\/DMSO.S275898","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref4","article-title":"Liver fibrosis associated with adipose tissue and liver inflammation in an obesity model","volume":"76","author":"Setyaningsih WA","year":"2021","unstructured":"Setyaningsih WA, Sari DC, Romi MM, Arfian N. Liver fibrosis associated with adipose tissue and liver inflammation in an obesity model. Med J Malaysia. 2021, 76:304-10.","journal-title":"Med J Malaysia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S67400","article-title":"Mechanism linking diabetes mellitus and obesity","volume":"7","author":"Al-Goblan AS","year":"2014","unstructured":"Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014, 7:587-91. 10.2147\/DMSO.S67400","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.152252","article-title":"Nonalcoholic fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?","volume":"4","author":"Ahmed MH","year":"2015","unstructured":"Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?. J Family Med Prim Care. 2015, 4:45-52. 10.4103\/2249-4863.152252","journal-title":"J Family Med Prim Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy T","year":"2016","unstructured":"Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol. 2016, 11:451-96. 10.1146\/annurev-pathol-012615-044224","journal-title":"Annu Rev Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021, 11:73. 10.3390\/metabo11020073","journal-title":"Metabolites"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo S","year":"2023","unstructured":"Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023, 43:2425-33. 10.1111\/liv.15695","journal-title":"Liver Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani A","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020, 111S:154170. 10.1016\/j.metabol.2020.154170","journal-title":"Metabolism"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher G","year":"2018","unstructured":"Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018, 14:99-114. 10.1038\/nrendo.2017.173","journal-title":"Nat Rev Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15906","article-title":"Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD","volume":"52","author":"Targher G","year":"2020","unstructured":"Targher G. Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD. Aliment Pharmacol Ther. 2020, 52:710-1. 10.1111\/apt.15906","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022, 39:1233-48. 10.1007\/s11095-022-03302-1","journal-title":"Pharm Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.","volume":"8","author":"Targher G","year":"2023","unstructured":"Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.. Lancet Gastroenterol Hepatol. 2023, 8:179-91. 10.1016\/S2468-1253(22)00338-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.970292","article-title":"The AMPK pathway in fatty liver disease","volume":"13","author":"Fang C","year":"2022","unstructured":"Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J, Han D. The AMPK pathway in fatty liver disease. Front Physiol. 2022, 13:970292. 10.3389\/fphys.2022.970292","journal-title":"Front Physiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01493-3","article-title":"Comparison of effects of injectable semaglutide and dulaglutide on oxidative stress and glucose variability in patients with type 2 diabetes mellitus: a prospective preliminary study","volume":"15","author":"Omachi T","year":"2024","unstructured":"Omachi T, Ohara M, Fujikawa T, et al.. Comparison of effects of injectable semaglutide and dulaglutide on oxidative stress and glucose variability in patients with type 2 diabetes mellitus: a prospective preliminary study. Diabetes Ther. 2024, 15:111-26. 10.1007\/s13300-023-01493-3","journal-title":"Diabetes Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101922","article-title":"The mTORC1\/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice","volume":"46","author":"Reis-Barbosa PH","year":"2022","unstructured":"Reis-Barbosa PH, Marcondes-de-Castro IA, Marinho TS, Aguila MB, Mandarim-de-Lacerda CA. The mTORC1\/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice. Clin Res Hepatol Gastroenterol. 2022, 46:101922. 10.1016\/j.clinre.2022.101922","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S384884","article-title":"Semaglutide may alleviate hepatic steatosis in T2DM combined with NFALD mice via miR-5120\/ABHD6","volume":"16","author":"Li R","year":"2022","unstructured":"Li R, Ye Z, She D, et al.. Semaglutide may alleviate hepatic steatosis in T2DM combined with NFALD mice via miR-5120\/ABHD6. Drug Des Devel Ther. 2022, 16:3557-72. 10.2147\/DDDT.S384884","journal-title":"Drug Des Devel Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.958218","article-title":"Gut microbiota: a new target for T2DM prevention and treatment","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Zhang J, Cheng Y, Zhu M, Xiao Z, Ruan G, Wei Y. Gut microbiota: a new target for T2DM prevention and treatment. Front Endocrinol (Lausanne). 2022, 13:958218. 10.3389\/fendo.2022.958218","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i4.15","article-title":"Diagnostic performance of central and generalized adiposity in detecting risk of diabetes mellitus in adolescents","volume":"22","author":"Musa DI","year":"2022","unstructured":"Musa DI, Agbana BE, Adeola MF, Idache BM, Abu S, Iwuagwu TE. Diagnostic performance of central and generalized adiposity in detecting risk of diabetes mellitus in adolescents. Afr Health Sci. 2022, 22:119-26. 10.4314\/ahs.v22i4.15","journal-title":"Afr Health Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002122","article-title":"Quantifying the underestimation of projected global diabetes prevalence by the International Diabetes Federation (IDF) Diabetes Atlas","volume":"9","author":"T\u00f6nnies T","year":"2021","unstructured":"T\u00f6nnies T, Rathmann W, Hoyer A, Brinks R, Kuss O. Quantifying the underestimation of projected global diabetes prevalence by the International Diabetes Federation (IDF) Diabetes Atlas. BMJ Open Diabetes Res Care. 2021, 9:e002122. 10.1136\/bmjdrc-2021-002122","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-01016-w","article-title":"Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction","volume":"21","author":"Xue C","year":"2023","unstructured":"Xue C, Chen K, Gao Z, et al.. Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction. Cell Commun Signal. 2023, 21:298. 10.1186\/s12964-022-01016-w","journal-title":"Cell Commun Signal"},{"key":"ref23","article-title":"Type 2 Diabetes (Nursing)","author":"Goyal R","year":"2023","unstructured":"Goyal R, Singhal M, Jialal I, Castano M. Type 2 Diabetes (Nursing). StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia U","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, et al.. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020, 21:6275. 10.3390\/ijms21176275","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/molecules19068289","article-title":"A PPAR\u03b3, NF-\u03baB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db\/db mice liver","volume":"19","author":"Jim\u00e9nez-Flores LM","year":"2014","unstructured":"Jim\u00e9nez-Flores LM, L\u00f3pez-Briones S, Mac\u00edas-Cervantes MH, Ram\u00edrez-Emiliano J, P\u00e9rez-V\u00e1zquez V. A PPAR\u03b3, NF-\u03baB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db\/db mice liver. Molecules. 2014, 19:8289-302. 10.3390\/molecules19068289","journal-title":"Molecules"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13435","article-title":"Insulin regulation of gluconeogenesis","volume":"1411","author":"Hatting M","year":"2018","unstructured":"Hatting M, Tavares CD, Sharabi K, Rines AK, Puigserver P. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci. 2018, 1411:21-35. 10.1111\/nyas.13435","journal-title":"Ann N Y Acad Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3881.2015.01.03","article-title":"Fatty liver disease in diabetes mellitus","volume":"4","author":"Bhatt HB","year":"2015","unstructured":"Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015, 4:101-8. 10.3978\/j.issn.2304-3881.2015.01.03","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i26.8377","article-title":"Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment","volume":"20","author":"Leite NC","year":"2014","unstructured":"Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014, 20:8377-92. 10.3748\/wjg.v20.i26.8377","journal-title":"World J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long MT","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022, 163:764-774.e1. 10.1053\/j.gastro.2022.06.023","journal-title":"Gastroenterology"},{"key":"ref30","article-title":"Non-alcoholic Fatty Liver Disease","author":"Ding L","year":"2022","unstructured":"Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Non-alcoholic Fatty Liver Disease. Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. von Eckardstein A, Binder CJ (ed): Springer, Cham (CH); 2022. 585-9."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i37.5327","article-title":"Efficacy and safety of semaglutide in non-alcoholic fatty liver disease","volume":"29","author":"Zhu K","year":"2023","unstructured":"Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol. 2023, 29:5327-38. 10.3748\/wjg.v29.i37.5327","journal-title":"World J Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061722","article-title":"Experimental data on the role of melatonin in the pathogenesis of nonalcoholic fatty liver disease","volume":"11","author":"Terziev D","year":"2023","unstructured":"Terziev D, Terzieva D. Experimental data on the role of melatonin in the pathogenesis of nonalcoholic fatty liver disease. Biomedicines. 2023, 11:1722. 10.3390\/biomedicines11061722","journal-title":"Biomedicines"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084173","article-title":"Remodeling of mitochondrial plasticity: the key switch from NAFLD\/NASH to HCC","volume":"22","author":"Longo M","year":"2021","unstructured":"Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of mitochondrial plasticity: the key switch from NAFLD\/NASH to HCC. Int J Mol Sci. 2021, 22:4173. 10.3390\/ijms22084173","journal-title":"Int J Mol Sci"},{"key":"ref34","article-title":"Nonalcoholic fatty liver disease: pathogenesis and intervention","volume":"2","author":"Hao L","year":"2023","unstructured":"Hao L, Chai Z. Nonalcoholic fatty liver disease: pathogenesis and intervention. Precis Nutr. 2023, 2:00029.","journal-title":"Precis Nutr"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0607-4","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms","volume":"15","author":"Saponaro C","year":"2015","unstructured":"Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015, 15:607. 10.1007\/s11892-015-0607-4","journal-title":"Curr Diab Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6638306","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship","volume":"2020","author":"Muzica CM","year":"2020","unstructured":"Muzica CM, Sfarti C, Trifan A, et al.. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship. Can J Gastroenterol Hepatol. 2020, 2020:6638306. 10.1155\/2020\/6638306","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.3.226","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship","volume":"34","author":"Rhee EJ","year":"2019","unstructured":"Rhee EJ. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship. Endocrinol Metab (Seoul). 2019, 34:226-33. 10.3803\/EnM.2019.34.3.226","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837237","article-title":"Oral administration of Bacillus toyonensis strain SAU-20 improves insulin resistance and ameliorates hepatic steatosis in type 2 diabetic mice","volume":"13","author":"Ren Z","year":"2022","unstructured":"Ren Z, Okyere SK, Xie L, et al.. Oral administration of Bacillus toyonensis strain SAU-20 improves insulin resistance and ameliorates hepatic steatosis in type 2 diabetic mice. Front Immunol. 2022, 13:837237. 10.3389\/fimmu.2022.837237","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.37349\/emed.2020.00019","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: Pathophysiological mechanisms shared between the two faces of the same coin","volume":"1","author":"Acierno C","year":"2020","unstructured":"Acierno C, Caturano A, Pafundi P, Nevola R, Adinolfi L, Sasso F. Nonalcoholic fatty liver disease and type 2 diabetes: Pathophysiological mechanisms shared between the two faces of the same coin. Explor Med. 2020, 1:287-306. 10.37349\/emed.2020.00019","journal-title":"Explor Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/87.1.217S","article-title":"Glucose metabolism and hyperglycemia","volume":"87","author":"Giugliano D","year":"2008","unstructured":"Giugliano D, Ceriello A, Esposito K. Glucose metabolism and hyperglycemia. Am J Clin Nutr. 2008, 87:217S-22S. 10.1093\/ajcn\/87.1.217S","journal-title":"Am J Clin Nutr"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021, 18:599-612. 10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith GI","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, et al.. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020, 130:1453-60. 10.1172\/JCI134165","journal-title":"J Clin Invest"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco R","year":"2012","unstructured":"Lomonaco R, Ortiz-Lopez C, Orsak B, et al.. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012, 55:1389-97. 10.1002\/hep.25539","journal-title":"Hepatology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.254","article-title":"Insulin resistance in type 2 diabetes: role of fatty acids","volume":"18 Suppl 2","author":"Arner P","year":"2002","unstructured":"Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev. 2002, 18 Suppl 2:S5-9. 10.1002\/dmrr.254","journal-title":"Diabetes Metab Res Rev"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli A","year":"2007","unstructured":"Gastaldelli A, Cusi K, Pettiti M, et al.. Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007, 133:496-506. 10.1053\/j.gastro.2007.04.068","journal-title":"Gastroenterology"},{"key":"ref46","article-title":"The entangled relationship between NAFLD, insulin resistance and obesity (ERNIRO)","volume":"4","author":"Nikhra V","year":"2019","unstructured":"Nikhra V. The entangled relationship between NAFLD, insulin resistance and obesity (ERNIRO). EC Endocrinol Metab Res. 2019, 4:349-59.","journal-title":"EC Endocrinol Metab Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2018.10.004","article-title":"Molecular and pathological events involved in the pathogenesis of diabetes-associated nonalcoholic fatty liver disease","volume":"9","author":"Bedi O","year":"2019","unstructured":"Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and pathological events involved in the pathogenesis of diabetes-associated nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019, 9:607-18. 10.1016\/j.jceh.2018.10.004","journal-title":"J Clin Exp Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/740671","article-title":"Protective effects of green tea extract against hepatic tissue injury in streptozotocin-induced diabetic rats","volume":"2012","author":"Abolfathi AA","year":"2012","unstructured":"Abolfathi AA, Mohajeri D, Rezaie A, Nazeri M. Protective effects of green tea extract against hepatic tissue injury in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med. 2012, 2012:740671. 10.1155\/2012\/740671","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117008","article-title":"Temporal relationship between diet-induced steatosis and onset of insulin\/leptin resistance in male Wistar rats","volume":"10","author":"Zhang L","year":"2015","unstructured":"Zhang L, Song H, Ge Y, Ji G, Yao Z. Temporal relationship between diet-induced steatosis and onset of insulin\/leptin resistance in male Wistar rats. PLoS One. 2015, 10:e0117008. 10.1371\/journal.pone.0117008","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos SA","year":"2015","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism. 2015, 64:60-78. 10.1016\/j.metabol.2014.10.012","journal-title":"Metabolism"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/360438","article-title":"Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal","volume":"2014","author":"Ayala A","year":"2014","unstructured":"Ayala A, Mu\u00f1oz MF, Arg\u00fcelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014, 2014:360438. 10.1155\/2014\/360438","journal-title":"Oxid Med Cell Longev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-013-0308-x","article-title":"Effects of binge ethanol on lipid homeostasis and oxidative stress in a rat model of nonalcoholic fatty liver disease","volume":"70","author":"Grasselli E","year":"2014","unstructured":"Grasselli E, Voci A, Demori I, De Matteis R, Compalati AD, Gallo G, Vergani L. Effects of binge ethanol on lipid homeostasis and oxidative stress in a rat model of nonalcoholic fatty liver disease. J Physiol Biochem. 2014, 70:341-53. 10.1007\/s13105-013-0308-x","journal-title":"J Physiol Biochem"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.2047-6310.2013.00189.x","article-title":"Adipose tissue insulin resistance in adolescents with and without type 2 diabetes","volume":"9","author":"Kelsey MM","year":"2014","unstructured":"Kelsey MM, Forster JE, Van Pelt RE, Reusch JE, Nadeau KJ. Adipose tissue insulin resistance in adolescents with and without type 2 diabetes. Pediatr Obes. 2014, 9:373-80. 10.1111\/j.2047-6310.2013.00189.x","journal-title":"Pediatr Obes"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/139239","article-title":"Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines","volume":"2013","author":"Makki K","year":"2013","unstructured":"Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm. 2013, 2013:139239. 10.1155\/2013\/139239","journal-title":"ISRN Inflamm"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg H","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010, 52:1836-46. 10.1002\/hep.24001","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20170046","article-title":"Effect of different \u03b3-subunit isoforms on the regulation of AMPK","volume":"474","author":"Willows R","year":"2017","unstructured":"Willows R, Navaratnam N, Lima A, Read J, Carling D. Effect of different \u03b3-subunit isoforms on the regulation of AMPK. Biochem J. 2017, 474:1741-54. 10.1042\/BCJ20170046","journal-title":"Biochem J"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19376","article-title":"AMPK: a novel target for treating hepatic fibrosis","volume":"8","author":"Liang Z","year":"2017","unstructured":"Liang Z, Li T, Jiang S, et al.. AMPK: a novel target for treating hepatic fibrosis. Oncotarget. 2017, 8:62780-92. 10.18632\/oncotarget.19376","journal-title":"Oncotarget"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2015.06.002","article-title":"Regulation of AMP-activated protein kinase by natural and synthetic activators","volume":"6","author":"Grahame Hardie D","year":"2016","unstructured":"Grahame Hardie D. Regulation of AMP-activated protein kinase by natural and synthetic activators. Acta Pharm Sin B. 2016, 6:1-19. 10.1016\/j.apsb.2015.06.002","journal-title":"Acta Pharm Sin B"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13698","article-title":"AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours","volume":"283","author":"Ross FA","year":"2016","unstructured":"Ross FA, MacKintosh C, Hardie DG. AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours. FEBS J. 2016, 283:2987-3001. 10.1111\/febs.13698","journal-title":"FEBS J"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2014.09.004","article-title":"AMPK: positive and negative regulation, and its role in whole-body energy homeostasis","volume":"33","author":"Hardie DG","year":"2015","unstructured":"Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 2015, 33:1-7. 10.1016\/j.ceb.2014.09.004","journal-title":"Curr Opin Cell Biol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1279","article-title":"Inhibition of adenosine monophosphate-activated protein kinase-3-hydroxy-3-methylglutaryl coenzyme A reductase signaling leads to hypercholesterolemia and promotes hepatic steatosis and insulin resistance","volume":"3","author":"Loh K","year":"2019","unstructured":"Loh K, Tam S, Murray-Segal L, et al.. Inhibition of adenosine monophosphate-activated protein kinase-3-hydroxy-3-methylglutaryl coenzyme A reductase signaling leads to hypercholesterolemia and promotes hepatic steatosis and insulin resistance. Hepatol Commun. 2019, 3:84-98. 10.1002\/hep4.1279","journal-title":"Hepatol Commun"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00244-16","article-title":"AMPK phosphorylates desnutrin\/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue","volume":"36","author":"Kim SJ","year":"2016","unstructured":"Kim SJ, Tang T, Abbott M, Viscarra JA, Wang Y, Sul HS. AMPK phosphorylates desnutrin\/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue. Mol Cell Biol. 2016, 36:1961-76. 10.1128\/MCB.00244-16","journal-title":"Mol Cell Biol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00225.2016","article-title":"Treatment of nonalcoholic fatty liver disease: role of AMPK","volume":"311","author":"Smith BK","year":"2016","unstructured":"Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016, 311:E730-40. 10.1152\/ajpendo.00225.2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.9b05495","article-title":"Apple polyphenol extract alleviates high-fat-diet-induced hepatic steatosis in male C57BL\/6 mice by targeting LKB1\/AMPK pathway","volume":"67","author":"Li D","year":"2019","unstructured":"Li D, Liu F, Wang X, Li X. Apple polyphenol extract alleviates high-fat-diet-induced hepatic steatosis in male C57BL\/6 mice by targeting LKB1\/AMPK pathway. J Agric Food Chem. 2019, 67:12208-18. 10.1021\/acs.jafc.9b05495","journal-title":"J Agric Food Chem"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169196","article-title":"mTOR: a potential new target in nonalcoholic fatty liver disease","volume":"23","author":"Feng J","year":"2022","unstructured":"Feng J, Qiu S, Zhou S, et al.. mTOR: a potential new target in nonalcoholic fatty liver disease. Int J Mol Sci. 2022, 23:9196. 10.3390\/ijms23169196","journal-title":"Int J Mol Sci"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2020.02.004","article-title":"Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease","volume":"4","author":"Chen H","year":"2020","unstructured":"Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Res. 2020, 4:15-22. 10.1016\/j.livres.2020.02.004","journal-title":"Liver Res"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.042","article-title":"mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4","volume":"19","author":"Park Y","year":"2017","unstructured":"Park Y, Reyna-Neyra A, Philippe L, Thoreen CC. mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4. Cell Rep. 2017, 19:1083-90. 10.1016\/j.celrep.2017.04.042","journal-title":"Cell Rep"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655731","article-title":"The mTOR-autophagy axis and the control of metabolism","volume":"9","author":"Deleyto-Seldas N","year":"2021","unstructured":"Deleyto-Seldas N, Efeyan A. The mTOR-autophagy axis and the control of metabolism. Front Cell Dev Biol. 2021, 9:655731. 10.3389\/fcell.2021.655731","journal-title":"Front Cell Dev Biol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00440-5","article-title":"SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation","volume":"3","author":"Bidault G","year":"2021","unstructured":"Bidault G, Virtue S, Petkevicius K, et al.. SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation. Nat Metab. 2021, 3:1150-62. 10.1038\/s42255-021-00440-5","journal-title":"Nat Metab"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.05.030","article-title":"mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT","volume":"67","author":"Gu Y","year":"2017","unstructured":"Gu Y, Albuquerque CP, Braas D, et al.. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT. Mol Cell. 2017, 67:128-138.e7. 10.1016\/j.molcel.2017.05.030","journal-title":"Mol Cell"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2016.11.008","article-title":"Epigenetics in non-alcoholic fatty liver disease","volume":"54","author":"Lee J","year":"2017","unstructured":"Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2017, 54:78-88. 10.1016\/j.mam.2016.11.008","journal-title":"Mol Aspects Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11365","article-title":"Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism","volume":"7","author":"Tang Y","year":"2016","unstructured":"Tang Y, Wallace M, Sanchez-Gurmaches J, et al.. Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism. Nat Commun. 2016, 7:11365. 10.1038\/ncomms11365","journal-title":"Nat Commun"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12080761","article-title":"\u03b1\/\u03b2-hydrolase domain-containing 6 (ABHD6)- a multifunctional lipid hydrolase","volume":"12","author":"Pusch LM","year":"2022","unstructured":"Pusch LM, Riegler-Berket L, Oberer M, Zimmermann R, Taschler U. \u03b1\/\u03b2-hydrolase domain-containing 6 (ABHD6)- a multifunctional lipid hydrolase. Metabolites. 2022, 12:761. 10.3390\/metabo12080761","journal-title":"Metabolites"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.202853","article-title":"Dual inhibition of alpha\/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons","volume":"286","author":"Marrs WR","year":"2011","unstructured":"Marrs WR, Horne EA, Ortega-Gutierrez S, et al.. Dual inhibition of alpha\/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. J Biol Chem. 2011, 286:28723-8. 10.1074\/jbc.M110.202853","journal-title":"J Biol Chem"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.08.047","article-title":"The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome","volume":"5","author":"Thomas G","year":"2013","unstructured":"Thomas G, Betters JL, Lord CC, et al.. The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome. Cell Rep. 2013, 5:508-20. 10.1016\/j.celrep.2013.08.047","journal-title":"Cell Rep"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.04.003","article-title":"\u03b1\/\u03b2-Hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion","volume":"19","author":"Zhao S","year":"2014","unstructured":"Zhao S, Mugabo Y, Iglesias J, et al.. \u03b1\/\u03b2-Hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion. Cell Metab. 2014, 19:993-1007. 10.1016\/j.cmet.2014.04.003","journal-title":"Cell Metab"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.02.076","article-title":"\u03b1\/\u03b2-hydrolase domain 6 deletion induces adipose browning and prevents obesity and type 2 diabetes","volume":"14","author":"Zhao S","year":"2016","unstructured":"Zhao S, Mugabo Y, Ballentine G, et al.. \u03b1\/\u03b2-hydrolase domain 6 deletion induces adipose browning and prevents obesity and type 2 diabetes. Cell Rep. 2016, 14:2872-88. 10.1016\/j.celrep.2016.02.076","journal-title":"Cell Rep"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13008","article-title":"Monoacylglycerol signalling and ABHD6 in health and disease","volume":"19 Suppl 1","author":"Poursharifi P","year":"2017","unstructured":"Poursharifi P, Madiraju SR, Prentki M. Monoacylglycerol signalling and ABHD6 in health and disease. Diabetes Obes Metab. 2017, 19 Suppl 1:76-89. 10.1111\/dom.13008","journal-title":"Diabetes Obes Metab"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi ZM","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2021, 160:912-8. 10.1053\/j.gastro.2020.11.051","journal-title":"Gastroenterology"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez M","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017, 67:829-46. 10.1016\/j.jhep.2017.05.016","journal-title":"J Hepatol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-020-00543-9","article-title":"Exercise as medicine: the impact of exercise training on nonalcoholic fatty liver disease","volume":"19","author":"Thorp A","year":"2020","unstructured":"Thorp A, Stine JG. Exercise as medicine: the impact of exercise training on nonalcoholic fatty liver disease. Curr Hepatol Rep. 2020, 19:402-11. 10.1007\/s11901-020-00543-9","journal-title":"Curr Hepatol Rep"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst JM","year":"2016","unstructured":"Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016, 65:1096-108. 10.1016\/j.metabol.2016.01.001","journal-title":"Metabolism"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos AF","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020, 12:60. 10.1186\/s13098-020-00570-y","journal-title":"Diabetol Metab Syndr"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55050166","article-title":"Dietary and pharmacological treatment of nonalcoholic fatty liver disease","volume":"55","author":"Jeznach-Steinhagen A","year":"2019","unstructured":"Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I, Shahnazaryan U, Kury\u0142owicz A. Dietary and pharmacological treatment of nonalcoholic fatty liver disease. Medicina (Kaunas). 2019, 55:166. 10.3390\/medicina55050166","journal-title":"Medicina (Kaunas)"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros VG","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, et al.. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010, 376:1916-22. 10.1016\/S0140-6736(10)61272-X","journal-title":"Lancet"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial","volume":"38","author":"Tang A","year":"2015","unstructured":"Tang A, Rabasa-Lhoret R, Castel H, et al.. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care. 2015, 38:1339-46. 10.2337\/dc14-2548","journal-title":"Diabetes Care"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.8.2169","article-title":"Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes","volume":"53","author":"Tiikkainen M","year":"2004","unstructured":"Tiikkainen M, H\u00e4kkinen AM, Korsheninnikova E, Nyman T, M\u00e4kimattila S, Yki-J\u00e4rvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004, 53:2169-76. 10.2337\/diabetes.53.8.2169","journal-title":"Diabetes"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20150125","article-title":"Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity","volume":"468","author":"Ford RJ","year":"2015","unstructured":"Ford RJ, Fullerton MD, Pinkosky SL, et al.. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J. 2015, 468:125-32. 10.1042\/BJ20150125","journal-title":"Biochem J"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12839","article-title":"Evolving role for pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia SL","year":"2021","unstructured":"Attia SL, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD\/NASH. Clin Transl Sci. 2021, 14:11-9. 10.1111\/cts.12839","journal-title":"Clin Transl Sci"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031437","article-title":"Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology","volume":"101","author":"Huang Y","year":"2022","unstructured":"Huang Y, Wang X, Yan C, et al.. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022, 101:e31437. 10.1097\/MD.0000000000031437","journal-title":"Medicine (Baltimore)"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam M","year":"2018","unstructured":"Dharmalingam M, Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018, 22:421-8. 10.4103\/ijem.IJEM_585_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"54","author":"Zein CO","year":"2011","unstructured":"Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011, 54:1610-9. 10.1002\/hep.24544","journal-title":"Hepatology"},{"key":"ref94","doi-asserted-by":"crossref","DOI":"10.1016\/S1665-2681(19)31539-X","article-title":"Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial","volume":"10","author":"Van Wagner LB","year":"2011","unstructured":"Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011, 10:277-86.","journal-title":"Ann Hepatol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283321d37","article-title":"Thiazolidinediones and the liver in humans","volume":"20","author":"Yki-J\u00e4rvinen H","year":"2009","unstructured":"Yki-J\u00e4rvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol. 2009, 20:477-83. 10.1097\/MOL.0b013e3283321d37","journal-title":"Curr Opin Lipidol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01176.x","article-title":"The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"12","author":"Polyzos SA","year":"2010","unstructured":"Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010, 12:365-83. 10.1111\/j.1463-1326.2009.01176.x","journal-title":"Diabetes Obes Metab"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi K","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al.. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016, 165:305-15. 10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo S","year":"2011","unstructured":"Ben-Shlomo S, Zvibel I, Shnell M, et al.. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011, 54:1214-23. 10.1016\/j.jhep.2010.09.032","journal-title":"J Hepatol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam SJ","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024, 84:729-35. 10.1007\/s40265-024-02045-0","journal-title":"Drugs"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni G","year":"2011","unstructured":"Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al.. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011, 31:1285-97. 10.1111\/j.1478-3231.2011.02462.x","journal-title":"Liver Int"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding X","year":"2006","unstructured":"Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology. 2006, 43:173-81. 10.1002\/hep.21006","journal-title":"Hepatology"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1067299","article-title":"Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study","volume":"15","author":"Rizvi AA","year":"2015","unstructured":"Rizvi AA, Patti AM, Giglio RV, et al.. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015, 15:1391-7. 10.1517\/14712598.2015.1067299","journal-title":"Expert Opin Biol Ther"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0480-8","article-title":"Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study","volume":"15","author":"Rizzo M","year":"2016","unstructured":"Rizzo M, Rizvi AA, Patti AM, et al.. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016, 15:162. 10.1186\/s12933-016-0480-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31886","article-title":"The GLP-1 receptor agonist semaglutide for the treatment of nonalcoholic steatohepatitis","volume":"74","author":"Dichtel LE","year":"2021","unstructured":"Dichtel LE. The GLP-1 receptor agonist semaglutide for the treatment of nonalcoholic steatohepatitis. Hepatology. 2021, 74:2290-2. 10.1002\/hep.31886","journal-title":"Hepatology"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck MA","year":"2019","unstructured":"Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019, 181:R211-34. 10.1530\/EJE-19-0566","journal-title":"Eur J Endocrinol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051362","article-title":"Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes","volume":"11","author":"Patti AM","year":"2023","unstructured":"Patti AM, Giglio RV, Allotta A, et al.. Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes. Biomedicines. 2023, 11:1362. 10.3390\/biomedicines11051362","journal-title":"Biomedicines"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094633","article-title":"Novel therapeutical approaches to managing atherosclerotic risk","volume":"22","author":"Giglio RV","year":"2021","unstructured":"Giglio RV, Pantea Stoian A, Al-Rasadi K, et al.. Novel therapeutical approaches to managing atherosclerotic risk. Int J Mol Sci. 2021, 22:4633. 10.3390\/ijms22094633","journal-title":"Int J Mol Sci"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040912","article-title":"Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes","volume":"9","author":"Patti AM","year":"2020","unstructured":"Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes. J Clin Med. 2020, 9:912. 10.3390\/jcm9040912","journal-title":"J Clin Med"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01548-y","article-title":"Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy chinese subjects: a double-blind, phase 1, randomized controlled trial","volume":"38","author":"Shi A","year":"2021","unstructured":"Shi A, Xie P, Nielsen LL, Skj\u00f8th TV, He X, Haugaard SP. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther. 2021, 38:550-61. 10.1007\/s12325-020-01548-y","journal-title":"Adv Ther"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli C","year":"2017","unstructured":"Sorli C, Harashima S-i, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:251-60. 10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3390\/nu14112217","article-title":"The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials","volume":"14","author":"Alabduljabbar K","year":"2022","unstructured":"Alabduljabbar K, Al-Najim W, le Roux CW. The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials. Nutrients. 2022, 14:2217. 10.3390\/nu14112217","journal-title":"Nutrients"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b7 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies M","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al.. Semaglutide 2\u00b7 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021, 397:971-84. 10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-021-00899-9","article-title":"Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists","volume":"20","author":"Okamoto A","year":"2021","unstructured":"Okamoto A, Yokokawa H, Nagamine T, Fukuda H, Hisaoka T, Naito T. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists. J Diabetes Metab Disord. 2021, 20:2121-8. 10.1007\/s40200-021-00899-9","journal-title":"J Diabetes Metab Disord"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214673","article-title":"Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"14","author":"Volpe S","year":"2022","unstructured":"Volpe S, Lisco G, Fanelli M, et al.. Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study. Nutrients. 2022, 14:4673. 10.3390\/nu14214673","journal-title":"Nutrients"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)02269-9","article-title":"Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests","volume":"78","author":"Schattenberg J","year":"2023","unstructured":"Schattenberg J, Gr\u00f8nb\u00e6k H, Kliers I, et al.. Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests. J Hepatol. 2023, 78:811-2. 10.1016\/S0168-8278(23)02269-9","journal-title":"J Hepatol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay S","year":"2023","unstructured":"Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023, 17:102849. 10.1016\/j.dsx.2023.102849","journal-title":"Diabetes Metab Syndr"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu S","year":"2022","unstructured":"Niu S, Chen S, Chen X, et al.. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022, 13:1046130. 10.3389\/fendo.2022.1046130","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen L","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, et al.. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017, 104:31-41. 10.1016\/j.ejps.2017.03.020","journal-title":"Eur J Pharm Sci"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:521-39. 10.1007\/s11154-021-09699-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen LB","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide\r\n. Front Endocrinol (Lausanne). 2019, 10:155. 10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann AJ","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al.. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018, 41:258-66. 10.2337\/dc17-0417","journal-title":"Diabetes Care"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog C","year":"2019","unstructured":"Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ. Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10). Pharmaceutics. 2019, 11:78. 10.3390\/pharmaceutics11020078","journal-title":"Pharmaceutics"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02685","article-title":"Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide","volume":"104","author":"Fonseca VA","year":"2019","unstructured":"Fonseca VA, Capehorn MS, Garg SK, et al.. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019, 104:4078-86. 10.1210\/jc.2018-02685","journal-title":"J Clin Endocrinol Metab"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"Christou GA","year":"2019","unstructured":"Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019, 20:805-15. 10.1111\/obr.12839","journal-title":"Obes Rev"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau J","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015, 58:7370-80. 10.1021\/acs.jmedchem.5b00726","journal-title":"J Med Chem"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.443","article-title":"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel","volume":"55","author":"Kapitza C","year":"2015","unstructured":"Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2015, 55:497-504. 10.1002\/jcph.443","journal-title":"J Clin Pharmacol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0677-1","article-title":"A randomized trial investigating the pharmacokinetics, pharmacodynamics, and safety of subcutaneous semaglutide once-weekly in healthy male Japanese and Caucasian subjects","volume":"35","author":"Ikushima I","year":"2018","unstructured":"Ikushima I, Jensen L, Flint A, Nishida T, Zacho J, Irie S. A randomized trial investigating the pharmacokinetics, pharmacodynamics, and safety of subcutaneous semaglutide once-weekly in healthy male Japanese and Caucasian subjects. Adv Ther. 2018, 35:531-44. 10.1007\/s12325-018-0677-1","journal-title":"Adv Ther"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0581-y","article-title":"Population pharmacokinetics of semaglutide for type 2 diabetes","volume":"10","author":"Overgaard RV","year":"2019","unstructured":"Overgaard RV, Delff PH, Petri KC, Anderson TW, Flint A, Ingwersen SH. Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Ther. 2019, 10:649-62. 10.1007\/s13300-019-0581-y","journal-title":"Diabetes Ther"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13186","article-title":"Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment","volume":"20","author":"Jensen L","year":"2018","unstructured":"Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018, 20:998-1005. 10.1111\/dom.13186","journal-title":"Diabetes Obes Metab"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0458-5","article-title":"Semaglutide s.c. once-weekly in type 2 diabetes: a population pharmacokinetic analysis","volume":"9","author":"Carlsson Petri KC","year":"2018","unstructured":"Carlsson Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Semaglutide s.c. once-weekly in type 2 diabetes: a population pharmacokinetic analysis. Diabetes Ther. 2018, 9:1533-47. 10.1007\/s13300-018-0458-5","journal-title":"Diabetes Ther"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0532-6","article-title":"Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects","volume":"56","author":"Hausner H","year":"2017","unstructured":"Hausner H, Derving Karsb\u00f8l J, Holst AG, Jacobsen JB, Wagner FD, Golor G, Anderson TW. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet. 2017, 56:1391-401. 10.1007\/s40262-017-0532-6","journal-title":"Clin Pharmacokinet"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1360274","article-title":"Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes","volume":"26","author":"Tan X","year":"2017","unstructured":"Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2017, 26:1083-9. 10.1080\/13543784.2017.1360274","journal-title":"Expert Opin Investig Drugs"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino Y","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T, et al.. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018, 20:378-88. 10.1111\/dom.13082","journal-title":"Diabetes Obes Metab"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda VR","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al.. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:355-66. 10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n B","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017, 5:341-54. 10.1016\/S2213-8587(17)30092-X","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/283918-mechanisms-of-non-alcoholic-fatty-liver-disease-and-beneficial-effects-of-semaglutide-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T16:20:36Z","timestamp":1723911636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/283918-mechanisms-of-non-alcoholic-fatty-liver-disease-and-beneficial-effects-of-semaglutide-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":137,"URL":"https:\/\/doi.org\/10.7759\/cureus.67080","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}